oxybutynin has been researched along with Down Syndrome in 3 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 9.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| " The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome." | 5.69 | The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome. ( Bottrill, K; Combs, D; Edgin, J; Gerken, B; Hsu, CH; La Rue, S; Matloff, D; Parthasarathy, S; Van Vorce, H, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Combs, D | 1 |
| Edgin, J | 1 |
| Hsu, CH | 1 |
| Bottrill, K | 1 |
| Van Vorce, H | 1 |
| Gerken, B | 1 |
| Matloff, D | 1 |
| La Rue, S | 1 |
| Parthasarathy, S | 1 |
| Wandresen, G | 1 |
| Sgarbi, F | 1 |
| Nisihara, R | 1 |
| Prasher, VP | 1 |
| Sachdeva, N | 1 |
| Adams, C | 1 |
| Haque, MS | 1 |
1 review available for oxybutynin and Down Syndrome
| Article | Year |
|---|---|
Management of contraceptives and menstrual complaints in patients with Down syndrome.
Topics: Contraception; Contraceptive Agents, Female; Contraceptive Devices, Female; Contraceptives, Oral, Ho | 2019 |
1 trial available for oxybutynin and Down Syndrome
| Article | Year |
|---|---|
The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.
Topics: Atomoxetine Hydrochloride; Child; Down Syndrome; Humans; Quality of Life; Sleep Apnea, Obstructive; | 2023 |
1 other study available for oxybutynin and Down Syndrome
| Article | Year |
|---|---|
Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
Topics: Alzheimer Disease; Analysis of Variance; Delayed-Action Preparations; Down Syndrome; Female; Humans; | 2013 |